China Medical Technologies Announces the SFDA Approval for its SPR System
October 19 2009 - 7:00AM
PR Newswire (US)
BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- China Medical
Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading
China-based medical device company that develops, manufactures and
markets advanced in-vitro diagnostic products, today announced that
the Company has received approval for its SPR- based analysis
system (the "SPR System") from the State Food and Drug
Administration of China (the "SFDA"). The SPR System utilizes
Surface Plasmon Resonance ("SPR") technology, a leading biosensor
technology in molecular biology. SPR technology has been
successfully used for the analysis of proteins, nucleic acids and
viruses for the past 20 years and has become a powerful platform
for life sciences, drug discovery, medicine and food safety. Human
papillomavirus ("HPV"), a common virus that infects the skin and
mucous membranes of humans and causes various kinds of warts as
well as cervical cancer, can be detected by adding pathological
samples on the HPV-DNA biosensor chip (the "HPV-DNA chip") and
analyzing the HPV-DNA chip with the SPR System. The SPR System is
label-free with high throughput, high speed and a high degree of
automation. The detection results can be displayed on a real-time
and online basis. The SPR System can be used in various potential
clinical diagnostic applications, such as the detection of
biomarkers related to infectious diseases, cancers, cardiovascular
disorders and immune system disorders. "We are pleased to receive
the SFDA approval for our SPR System on a timely basis," commented
Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the
Company. "We have commenced the delivery of our SPR Systems to our
large hospital customers and believe that more and more women will
benefit from the use of our SPR system and HPV-DNA chips together
with our cervical cancer FISH probes, both of which can guide
physicians to determine and apply effective treatment in the early
stages of cervical diseases to reduce the risk of cervical cancer
as well as early detection of cervical cancer." About China Medical
Technologies, Inc. China Medical Technologies is a leading
China-based medical device company that develops, manufactures and
markets advanced in-vitro diagnostic (IVD) products using Enhanced
Chemiluminescence (ECLIA) technology, Fluorescent in situ
Hybridization (FISH) technology and Surface Plasmon Resonance (SPR)
technology to detect and monitor various diseases and disorders.
For more information, please visit http://www.chinameditech.com/ .
Safe Harbor Statement This press release contains forward-looking
statements. These statements constitute "forward-looking"
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Such statements
involve certain risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. Further information regarding these and other risks is
included in the Company's filings with the U.S. Securities and
Exchange Commission, including its annual report on Form 20-F. The
Company does not undertake any obligation to update any
forward-looking statement as a result of new information, future
events or otherwise, except as required under applicable law. For
more information, please contact: Winnie Yam Tel: +852-2511-9808
Email: DATASOURCE: China Medical Technologies, Inc. CONTACT: Winnie
Yam, +852-2511-9808, or Web site: http://www.chinameditech.com/
Copyright